PDS Biotechnology Corporation

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PDS Biotechnology advances oncology pipeline with promising trial results

PDS Biotechnology's strategic focus on oncology pipeline advancement, strong interim trial results, and financial stability position the company for continued growth and clinical success.
While facing financial challenges and operational complexities, the company's proactive approach to trial designs, regulatory engagements, and commercialization strategies offer promising opportunities for future development.
Overall, PDS Biotechnology's performance in 2022 reflects a balance of achievements, challenges, and opportunities, underscoring a commitment to innovation and clinical progress in the oncology space.

PDS Biotechnology reports Q1 loss, progresses promising cancer therapies

PDS Biotechnology's Q1 performance reflects ongoing investment in clinical development.
Strengths lie in innovative therapies, upcoming Phase 3 trial, and manufacturing progress.
Challenges include financial losses, competition, and meeting trial milestones.
Opportunities exist in clinical advancements, partnerships, market demand, and investor confidence.

PDS Biotechnologies reports Q2 loss, progresses in clinical trials

PDS Biotechnologies faces increased expenses but maintains strong funding for future operations.
Progress in clinical programs and upcoming milestones provide growth opportunities.
Challenges include trial requirements and enrollment timelines, but company is managing well.

PDS Biotechnology reports promising cancer therapy results amidst financial challenges

PDS Biotechnology demonstrates clinical success with PDS0101 and PDS01ADC, while facing financial pressures and operational challenges.
Strategic strengths in oncology programs and proactive clinical development position the company for growth and potential partnerships.
Opportunities lie in diversification with PDS0202, expanding the pipeline, and leveraging positive data from upcoming investigator-initiated trials.
Navigating financial challenges, operational complexities, and maximizing therapeutic potential will be key for PDS Biotechnology's future success.

PDS Biotechnology reports Q4 loss, focuses on innovative cancer trials

PDS Biotechnology's Q4 2023 Earnings Call highlighted financial performance, strategic focus on innovative clinical trials, and promising data-driven decisions.
The company's strengths lie in its collaborations with the National Cancer Institute, advancements in Phase II programs, and a healthy cash balance supporting future funding.
Challenges include managing rising operating expenses, delivering on trial outcomes, and navigating market competition, while opportunities exist in establishing leadership in cancer therapies and attracting investors.
Overall, PDS Biotechnology's emphasis on data-driven strategies, strong financial position, and commitment to advancing cancer treatments position it for potential growth and success in the biopharmaceutical industry.

PDS Biotechnology reports Q3 loss, optimistic on Versamune HPV potential

PDS Biotechnology Corporation's Q3 2024 performance reflected increased R&D expenses and strategic trial design modifications.
Despite financial challenges and competitive pressures, the company remains optimistic about the potential of Versamune HPV.
Opportunities lie in advancing the VERSATILE-003 trial, leveraging positive feedback, and addressing unmet medical needs in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

Ongoing program to focus on checkpoint inhibitor refractory patients following data presented at ASCO 2022 demonstrating 77% survival at a median of 12 months Ongoing program to focus on checkpoint inhibitor refractory patients following data presented at ASCO 2022 demonstrating 77% survival at a median of 12 months

PDS Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers

FLORHAM PARK, N.J., Aug. 24, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® and Infectimune™ T cell activating technologies, today announced that it has entered into a debt financing agreement led by Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) to provide up to a $35.0 million term loan.

PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance

The consensus price target hints at a 265.3% upside potential for PDS Biotechnology (PDSB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in PDS Biotechnology (PDSB)? Wall Street Analysts Think 265%

Netscientific PLC said it was encouraged by the progress being made at PDS Biotech after the US portfolio company released second-quarter results yesterday. Ilian Iliev, NetScientific's CEO, added: "We are pleased with the continued progress by PDS Biotech in its Phase 2 trials and broader corporate development, coming despite the ongoing volatility in the biotech public markets.

Netsceintific pleased with progress at PDS Biotech

PDS Biotechnology Corporation (NASDAQ:PDSB ) Q2 2022 Results Earnings Conference Call August 8, 2022 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matthew Hill - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald James Molloy - Alliance Global Partners Leland Gershell - Oppenheimer & Co. Joseph Pantginis - H. C. Wainwright & Co. Robert LeBoyer - Noble Capital Markets Operator Greetings.

PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q2 2022 Results - Earnings Call Transcript

FLORHAM PARK, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® and Infectimune™ T cell-activating technologies, will discuss its financial results for the quarter ended June 30, 2022 and provide a business update on its conference call today.

PDS Biotech Reports Second Quarter 2022 Financial Results and Provides Business Update

Safety evaluation of 43 patients with no grade 3 or higher treatment-related adverse events Safety evaluation of 43 patients with no grade 3 or higher treatment-related adverse events

PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications

PDS0202 neutralized multiple strains of influenza and provided protection against infection in preclinical studies PDS0202 neutralized multiple strains of influenza and provided protection against infection in preclinical studies

PDS Biotechnology Announces Presentation of Universal Flu Vaccine Preclinical Data at the 41st American Society of Virology Meeting

Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

PDS Biotechnology Appoints Spencer Brown as Senior Vice President, General Counsel

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PDS Biotechnology's (NASDAQ: PDSB) lead drug candidate PDS0101 in combination with KEYTRUDA (pembrolizumab) for the treatment of patients with recurrent or metastatic HPV16-positive head and neck cancer.

PDS Biotechnology Gains On FDA Fast Track Designation For Lead Candidate

Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16+ cancers; both CPI naive and CPI refractory patients were helped. Positive results were also announced from the phase 2 study using PDS0101 + Keytruda for recurrent or metastatic head and neck cancer patients.

PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data

Preliminary data from first 19 patients treated with PDS0101 in combination with KEYTRUDA ® (pembrolizumab) demonstrates 41% response rate thus far for first line recurrent or metastatic head and neck cancer, in comparison to the published results of approximately 19% for approved checkpoint inhibitors used as monotherapy for recurrent or metastatic head and neck cancer*

PDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO 2022

77% of checkpoint inhibitor (CPI) refractory patients alive at median follow up of 12 months

PDS Biotech Announces Presentation of Data from NCI-Led Triple Combination Phase 2 Clinical Trial in Advanced, Refractory HPV-Positive Cancers at ASCO 2022

FLORHAM PARK, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that its management will present at the H.C. Wainwright Global Investment Conference and the LD Micro Invitational and will participate at the UBS Healthcare Virtual One-on-One Day.

PDS Biotech to Participate at Upcoming Investor Conferences

NetScientific PLC (AIM:NSCI) has noted first-quarter results from its portfolio company PDS Biotechnology, which also has results from key trials upcoming at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in June. Abstract # 6041 will summarize updates to the preliminary efficacy and safety data from the PDS-sponsored VERSATILE-002 Phase 2 clinical trial, which is evaluating PDS0101 in combination with Merck's anti-PD-1 therapy KEYTRUDA for the treatment of recurrent or metastatic HPV16-positive head and neck cancer.

NetSceintific highlights PDS Biotech's key posters at upcoming ASCO conference

PDS Biotechnology Corporation. (NASDAQ:PDSB ) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matthew Hill - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Leland Gershell - Oppenheimer Laura Suriel - Alliance Global Partners Robert LeBoyer - Noble Capital Operator Hello and welcome to PDS Biotechnology First Quarter 2022 Earnings Call and Webcast.

PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q1 2022 Results - Earnings Call Transcript

Company to host conference call and webcast today, May 11, 2022, at 8:00 AM EDT Company to host conference call and webcast today, May 11, 2022, at 8:00 AM EDT

PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results

FLORHAM PARK, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced the titles of two abstracts accepted for poster presentations during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 3-7, 2022.

PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q4 2021 Results - Earnings Call Transcript

NetScientific PLC (AIM:NSCI) says its portfolio company, PDS Biotechnology Corporation (NASDAQ:PDSB) (Nasdaq: PDSB), made good progress through 2021, hitting a number of milestones. Ilian Iliev, NetScientific chief executive, said: "PDS has continued the steady progress and build-out of the business, progressing multiple clinical applications of the Versamune platform in immuno-oncology and infectious disease vaccines.

NetSceinttific notes 'steady progress' by portfolio company PDS

Company to host conference call and webcast today, March 31, 2022, at 8:00 AM EDT Company to host conference call and webcast today, March 31, 2022, at 8:00 AM EDT

PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results

FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that it has changed the date of its previously announced 2021 fourth quarter and full year earnings release call from Wednesday, March 23, 2022 to 8:00 AM EDT on Thursday, March 31, 2022 as PDS Biotech needs additional time to complete its audit and file its Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Following the release, management will host a conference call to review the financial results and provide a business update.

PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call

NCI achieves the enrollment objective of thirty patients in the checkpoint inhibitor refractory arm of the study NCI achieves the enrollment objective of thirty patients in the checkpoint inhibitor refractory arm of the study

PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers

Preliminary safety data has shown that PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe and well tolerated without evidence of enhanced or significant toxicity

PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium

PDS0101 could become the first line therapy in HPV-16 associated cancers (40,500 cases/year in the U.S. or $6 billion/year revenue opportunity).

News for PDS Biotechnology Corporation Stock (PDSB)